Search
for
Sort by
Research 31–60 of 1000+
- 277 An open label pilot clinical trial of the JAK inhibitor tofacitinib for alopecia areata
- Off-label use of biologics and janus kinase (JAK) inhibitors for scarring alopecias: a narrative review
- 331 An open label clinical trial of the JAK inhibitor tofacitinib for alopecia areata
- Post-marketing safety signals of four JAK inhibitors for alopecia areata: an indication-restricted FAERS pharmacovigilance study
- Switching JAK inhibitors: evaluating baricitinib’s effectiveness in alopecia areata after tofacitinib failure
- JAK-inhibitors in the therapy of comorbid diseases – atopic dermatitis and alopecia areata: literature review and experience of clinical practice
- Adverse events in patients treated with Jak‐inhibitors for alopecia areata: A systematic review
- Short-term malignancy risk of JAK inhibitors in severe alopecia areata: a multicenter cohort study
- Efficacy and safety of JAK inhibitors in treating lichen planopilaris or frontal fibrosing alopecia
- Infectious events in patients with alopecia areata treated with JAK inhibitors: low burden and minimal impact on persistence in treatment
- Randomized Controlled Trial of the Topical Jak Inhibitor Delgocitinib Cream in Patients with Frontal Fibrosing Alopecia
- 075 Clinical investigation of JAK inhibitor Tofacitinib in scarring alopecias
- JAK Inhibitor Safety in Atopic Dermatitis and Alopecia Areata: A 4.5-Year Real-World Retrospective Cohort Study
- A Review on the Use and Effectiveness of JAK Inhibitor in the Management of Lichen Planopilaris
- Treatment of Alopecia Areata with Oral JAK Inhibitor : Focusing on Clinical Outcomes with Baricitinib
- Case Report: Repigmentation and complete hair regrowth in an 11-year-old preadolescent with alopecia totalis treated with a JAK inhibitor
- Ritlecitinib in Alopecia Areata: A 24‐Week Real‐World Experience Contrasting JAK Inhibitor‐Naïve and JAK Inhibitor‐Experienced Patients
- JAK Inhibitor Therapy in Alopecia Areata with Latent Hepatitis B Virus or Tuberculosis Infection: A Safety Assessment
- JAK Inhibitor Therapy in Alopecia Areata with Latent Hepatitis B Virus or Tuberculosis Infection: A Safety Assessment
- 0433 JAK inhibitor halts the progression of acute exacerbation of alopecia areata
- Short-term Efficacy of Tofacitinib, a JAK Inhibitor, in IFIH1-related Aicardi-Goutières Syndrome
- Clinical and Dermoscopic Evaluation of the Safety and Efficacy of Oral baricitinib (JAK Inhibitor) in Treatment of Localized Vitiligo Either Alone or with Topical Tacrolimus
- Efficacy and Tolerability of Brevilin-A, a Natural JAK Inhibitor, in Pediatric Alopecia Areata: A Case Series
- Tofacitinib: The selected selective JAK inhibitor in paediatric dermatology
- 43647 Treatment of Refractory Folliculitis Decalvans with the Topical JAK Inhibitor Tofacitinib
- JAK inhibitor deuruxolitinib shows encouraging hair re-growth in alopecia areata
- JAK Inhibitor Baricitinib in the Treatment of Oral Lichen Planus: A Case Report
- The development of oral hairy leukoplakia during JAK inhibitor baricitinib therapy
- 73571 The real-world impact of JAK inhibitor treatment on anxiety and depression outcomes and the role of eyebrow and eyelash hair regrowth in alopecia areata: TARGET-DERM
- Treatment Response to JAK Inhibitors in Long-standing Alopecia Areata (≥8 Years): A Real-world Observational Study